These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 6509452)

  • 1. Study of erythrocyte mean corpuscular volume during cytotoxic therapy as a predictive parameter of the risk of secondary leukemia in Hodgkin's disease.
    de Gramont A; Rioux E; Drolet Y; Delage JM
    Cancer Treat Rep; 1984 Dec; 68(12):1467-70. PubMed ID: 6509452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in the mean corpuscular volume during the cytotoxic treatment of cancer and risk of secondary leukemia. Preliminary results].
    de Gramont A; Rioux E; Drolet Y; Barry A; Delage JM
    Sem Hop; 1984 Mar; 60(14):961-6. PubMed ID: 6326284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute leukemia in patients treated for Hodgkin's disease].
    Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
    Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
    Lipton JH; Gospodarowicz M; Reingold S
    Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia following Hodgkin's disease.
    Kaldor JM; Day NE; Clarke EA; Van Leeuwen FE; Henry-Amar M; Fiorentino MV; Bell J; Pedersen D; Band P; Assouline D
    N Engl J Med; 1990 Jan; 322(1):7-13. PubMed ID: 2403650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup.
    Coltman CA; Dixon DO
    Cancer Treat Rep; 1982 Apr; 66(4):1023-33. PubMed ID: 7074630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of second tumors in patients with Hodgkin's disease (review of the literature and personal data)].
    Kanaev SV; Kholin AV; Gershanovich ML; Malinin AP
    Vopr Onkol; 1987; 33(5):11-8. PubMed ID: 3590664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrocyte mean corpuscular volume during cytotoxic therapy and the risk of secondary leukemia.
    de Gramont A; Rioux E; Drolet Y; Delage JM
    Cancer; 1985 Feb; 55(3):493-5. PubMed ID: 4038378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease.
    Henry-Amar M
    J Natl Cancer Inst; 1983 Nov; 71(5):911-6. PubMed ID: 6580491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent abnormalities in red cell parameters following treatment of lymphoma.
    Meytes D; Leshno D; Berkowicz M; Modan M; Ramot B
    Leuk Lymphoma; 1994 Oct; 15(3-4):341-5. PubMed ID: 7866284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocyte mean corpuscular volume during cytotoxic therapy is a predictive parameter of secondary leukemia in Hodgkin's disease.
    de Gramont A; Louvet C; Krulik M; Smadja N; Donadio D; Laporte JP; Brissaud P; Delâge JM; Drolet Y; Rioux E
    Cancer; 1987 Jan; 59(2):301-4. PubMed ID: 3467821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of long-term side effects--in particular induced leukemias following treatment for Hodgkin's disease.
    De Renzis C; Cellini N; Ausili Cefaro GP; Mantini G; Parisi S; Smaniotto D
    Rays; 1986; 11(2):109-13. PubMed ID: 3602444
    [No Abstract]   [Full Text] [Related]  

  • 14. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.
    Pedersen-Bjergaard J; Larsen SO
    N Engl J Med; 1982 Oct; 307(16):965-71. PubMed ID: 7110299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
    Glanzmann C; Veraguth A; Lütolf UM
    Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study.
    Glicksman AS; Pajak TF; Gottlieb A; Nissen N; Stutzman L; Cooper MR
    Cancer Treat Rep; 1982 Apr; 66(4):1035-44. PubMed ID: 6951632
    [No Abstract]   [Full Text] [Related]  

  • 19. [Acute leukemias and solid tumors in the course of Hodgkin disease].
    Jacquillat C; Auclerc G; Weil M; Auclerc MF; Maral J
    Bull Cancer; 1983; 70(1):61-6. PubMed ID: 6687694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.